Literature DB >> 21385171

Decreased expression of interleukin-27 in immune thrombocytopenia.

Xin-guang Liu1, Juan Ren, Yuan Yu, Lin Sun, Yan Shi, Ping Qin, Lei Yang, Shi-hui Ma, Xiao-yuan Dong, Dao-xin Ma, Xun Qu, Cheng-shan Guo, Chun-yan Chen, Ming Hou, Jun Peng.   

Abstract

Primary immune thrombocytopenia (ITP) is an immune-mediated disorder in which disturbed cytokine profiles have been found. Interleukin-27 (IL27) has been shown to bear both proinflammatory and anti-inflammtory effects. In the present study, plasma levels of IL27, interferon gamma (IFNG), IL4, and IL17A were determined by enzyme-linked immunosorbent assay in 23 active ITP patients, 20 patients in remission and 20 healthy controls. mRNA expression levels of IL27, EBI3, IL27 receptor (IL27RA), IL17A and RAR-related orphan receptor C (RORC) were determined by real-time quantitative polymerase chain reaction. Significantly lower levels of plasma IL27, IL4, mRNA expression of IL27, EBI3 and higher levels of plasma IFNG as well as mRNA expression of IL17A, RORC were observed in active ITP patients compared with healthy controls or patients in remission. No statistical difference was found in IL27RA mRNA expression or plasma IL17A levels among active ITP patients and controls. A negative correlation was found between the IL27 and RORC mRNA expression levels in active ITP patients. Our data demonstrated that active ITP patients had decreased plasma and mRNA expression levels of IL27, suggesting that it might be involved in the pathophysiological process of ITP.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21385171     DOI: 10.1111/j.1365-2141.2011.08614.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Interleukin 27 inhibits cytotoxic T-lymphocyte-mediated platelet destruction in primary immune thrombocytopenia.

Authors:  Hai Zhou; Ji-Hua Qiu; Tong Wang; Ying-Yi Yu; Xue-Na Liu; Xin Li; Ya-Wen Wang; Yu Hou; Li-Zhen Li; Xin-Guang Liu; Ming Hou; Jun Peng
Journal:  Blood       Date:  2014-10-08       Impact factor: 22.113

2.  IL-23/Th17 pathway and IL-17A gene polymorphism in Egyptian children with immune thrombocbytopenic purpura.

Authors:  Ahlam M Ismail; Aliaa M Higazi; Hanan M Nomeir; Naglaa M Farag
Journal:  Ital J Pediatr       Date:  2021-08-26       Impact factor: 2.638

Review 3.  T cell immune abnormalities in immune thrombocytopenia.

Authors:  Xuebin Ji; Liping Zhang; Jun Peng; Ming Hou
Journal:  J Hematol Oncol       Date:  2014-10-02       Impact factor: 17.388

Review 4.  The Centenary of Immune Thrombocytopenia - Part 1: Revising Nomenclature and Pathogenesis.

Authors:  Rita Consolini; Annalisa Legitimo; Maria Costanza Caparello
Journal:  Front Pediatr       Date:  2016-10-19       Impact factor: 3.418

Review 5.  Soluble fibrinogen like protein 2 (sFGL2), the novel effector molecule for immunoregulation.

Authors:  Xin-Guang Liu; Yu Liu; Feng Chen
Journal:  Oncotarget       Date:  2017-01-10

6.  High-Dose Dexamethasone Alters the Increase in Interleukin-16 Level in Adult Immune Thrombocytopenia.

Authors:  Xinru Wang; Lizhen Li; Yuanjian Wang; Xin Li; Qi Feng; Yu Hou; Chunhong Ma; Chengjiang Gao; Ming Hou; Jun Peng
Journal:  Front Immunol       Date:  2019-03-18       Impact factor: 7.561

7.  Contribution of interleukin 27 serum level to pathogenesis and prognosis in children with immune thrombocytopenia.

Authors:  Tamer Hassan; Doaa Abdel Rahman; Nermin Raafat; Manar Fathy; Mohamed Shehab; Ahmed Hosny; Reham Fawzy; Marwa Zakaria
Journal:  Medicine (Baltimore)       Date:  2022-06-24       Impact factor: 1.817

8.  Interleukin-18 and miR-130a in severe sepsis patients with thrombocytopenia.

Authors:  Yao-Li Cui; Bing Wang; Hong-Mei Gao; Ying-Hong Xing; Jian Li; Hong-Jie Li; Zhu Lin; Yong-Qiang Wang
Journal:  Patient Prefer Adherence       Date:  2016-03-11       Impact factor: 2.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.